ZVRA
Income statement / Annual
Last year (2024), Zevra Therapeutics, Inc.'s total revenue was $23.61 M,
a decrease of 14.02% from the previous year.
In 2024, Zevra Therapeutics, Inc.'s net income was -$105.51 M.
See Zevra Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$23.61 M |
$27.46 M |
$10.16 M |
$28.65 M |
$13.29 M |
$12.84 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$7.42 M
|
$2.95 M
|
$222.00 K
|
$2.06 M
|
$1.31 M
|
$2.95 M
|
$324.00 K
|
$336.00 K
|
$175.00 K
|
$84.00 K
|
| Gross Profit |
$16.20 M
|
$24.52 M
|
$9.94 M
|
$26.59 M
|
$11.98 M
|
$9.89 M
|
-$324.00 K
|
-$336.00 K
|
-$175.00 K
|
-$84.00 K
|
| Gross Profit Ratio |
0.69
|
0.89
|
0.98
|
0.93
|
0.9
|
0.77
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$42.10 M
|
$39.81 M
|
$19.80 M
|
$10.16 M
|
$8.84 M
|
$19.42 M
|
$41.76 M
|
$20.59 M
|
$20.47 M
|
$13.93 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$15.34 M
|
$8.70 M
|
$7.92 M
|
$10.82 M
|
$12.51 M
|
$12.77 M
|
$14.00 M
|
$8.88 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
-$305.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$54.87 M
|
$35.09 M
|
$15.04 M
|
$8.70 M
|
$7.92 M
|
$10.82 M
|
$12.51 M
|
$12.77 M
|
$14.00 M
|
$8.88 M
|
| Other Expenses |
$6.24 M
|
-$775.00 K
|
$17.66 M
|
$0.00
|
$828.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$103.20 M
|
$74.12 M
|
$52.50 M
|
$18.86 M
|
$17.59 M
|
$30.23 M
|
$54.27 M
|
$33.37 M
|
$34.47 M
|
$22.81 M
|
| Cost And Expenses |
$110.62 M
|
$77.07 M
|
$52.73 M
|
$20.92 M
|
$18.90 M
|
$33.18 M
|
$54.27 M
|
$33.37 M
|
$34.47 M
|
$22.81 M
|
| Interest Income |
$2.18 M
|
$4.54 M
|
$1.51 M
|
$261.00 K
|
$89.00 K
|
$309.00 K
|
$420.00 K
|
$365.00 K
|
$353.00 K
|
$32.00 K
|
| Interest Expense |
$7.35 M
|
$1.50 M
|
$335.00 K
|
$376.00 K
|
$7.09 M
|
$6.51 M
|
$7.09 M
|
$7.34 M
|
$7.13 M
|
$2.67 M
|
| Depreciation & Amortization |
$6.39 M
|
$1.01 M
|
$944.00 K
|
$257.00 K
|
$273.00 K
|
$304.00 K
|
$324.00 K
|
$336.00 K
|
$175.00 K
|
$84.00 K
|
| EBITDA |
-$76.40 M |
-$43.54 M |
-$25.53 M |
-$7.89 M |
-$5.43 M |
-$17.73 M |
-$53.94 M |
-$33.03 M |
-$34.30 M |
-$22.73 M |
| EBITDA Ratio |
-3.24
|
-1.59
|
-2.51
|
-0.28
|
-0.41
|
-1.38
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-3.68
|
-1.81
|
-4.19
|
0.27
|
-0.42
|
-1.58
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$3.14 M
|
$3.56 M
|
$15.76 M
|
-$16.25 M
|
-$7.19 M
|
-$4.21 M
|
-$689.00 K
|
-$10.06 M
|
$20.95 M
|
-$31.82 M
|
| Income Before Tax |
-$90.14 M
|
-$46.05 M
|
-$26.81 M
|
-$8.52 M
|
-$12.79 M
|
-$24.54 M
|
-$56.59 M
|
-$43.43 M
|
-$16.53 M
|
-$54.64 M
|
| Income Before Tax Ratio |
-3.82
|
-1.68
|
-2.64
|
-0.3
|
-0.96
|
-1.91
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$15.37 M
|
$0.00
|
-$33.00 K
|
$34.00 K
|
-$34.00 K
|
-$22.00 K
|
-$126.00 K
|
-$43.00 K
|
-$15.00 K
|
$26.00 K
|
| Net Income |
-$105.51 M
|
-$46.05 M
|
-$26.77 M
|
-$8.56 M
|
-$12.76 M
|
-$24.52 M
|
-$56.47 M
|
-$43.39 M
|
-$16.52 M
|
-$54.66 M
|
| Net Income Ratio |
-4.47
|
-1.68
|
-2.63
|
-0.3
|
-0.96
|
-1.91
|
0
|
0
|
0
|
0
|
| EPS |
-2.28 |
-1.3 |
-0.78 |
-2.11 |
-3.21 |
-13.23 |
-50.39 |
-47.37 |
-18.1 |
-118.69 |
| EPS Diluted |
-2.28 |
-1.3 |
-0.78 |
-2.11 |
-3.21 |
-13.23 |
-50.39 |
-47.37 |
-18.1 |
-118.69 |
| Weighted Average Shares Out |
$46.25 M
|
$35.45 M
|
$34.49 M
|
$29.77 M
|
$3.98 M
|
$1.85 M
|
$1.12 M
|
$915.81 K
|
$912.32 K
|
$460.54 K
|
| Weighted Average Shares Out Diluted |
$46.25 M
|
$35.45 M
|
$34.49 M
|
$29.77 M
|
$3.98 M
|
$1.85 M
|
$1.12 M
|
$915.81 K
|
$912.32 K
|
$460.54 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
